Familial chylomicronemia syndrome (FCS) is a rare genetic disease that causes very high triglyceride levels in the body. Tryngolza (olezarsen) was approved in 2024 and is the first and only ...

The evidence for elevated triglycerides, as a cardiac risk factor, is nowhere near as well understood as the risk from high LDL and low HDL cholesterol. However, the growing body of epidemiologic ...

Every time you get a lipid profile test, a doctor is likely to check for your cholesterol and triglyceride levels. While both of these lipids, or fats, found in the blood increase the risk of heart ...

Monthly olezarsen reduced triglycerides and apolipoprotein B in patients with hypertriglyceridemia but may have no impact on ...

In a small, short-term, Phase 2 clinical trial in adults, a first-of-its-kind medication reduced triglyceride levels in most patients by more than 60%. Called DR10624, the medication activates three ...

Clin Lipidology. 2009;4(4):425-437. Clinical event trials are urgently needed to assess treatment strategies for dyslipidemia management, including POM3 treatment, in patients with ...

ATLANTA, GA—Investigational agents that work by inhibiting apolipoprotein C-III (APOC3) are effective at reducing triglyceride levels, two phase IIb studies show. In Bridge-TIMI 73a, treatment with ...

Amarin Corporation plc (NASDAQ: AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted the important scientific and educational ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its ...

You have had the cholesterol conversation with your doctor enough times that the numbers feel familiar. LDL, HDL, ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational ...